search
Back to results

Gene - Diet Interactions (Genediet)

Primary Purpose

Insulin Sensitivity

Status
Completed
Phase
Not Applicable
Locations
Finland
Study Type
Interventional
Intervention
PUFA-diet
SAFA-diet
Sponsored by
Marjukka Kolehmainen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Insulin Sensitivity focused on measuring Gene-diet interaction, PPARgamma gene, Pro12Ala, Fatty acids, Dietary modification, Insulin sensitivity, Glucose metabolism

Eligibility Criteria

40 Years - 65 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI >20kg/m2 <29kg/m2
  • Pro12Pro and Ala12Ala genotypes of PPARG Pro12Ala polymorphism
  • participation to METSIM-study (METabolic Syndrome in Men, currently >10000 men included from the population living in Kuopio, principal investigator Markku Laakso)
  • normoglycemia

Exclusion Criteria:

  • type 2 diabetes
  • other chronic diseases

Sites / Locations

  • University of Eastern Finland

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

P/S-ratio 1.0

P/S-ration 0.3

Arm Description

Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.

Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.

Outcomes

Primary Outcome Measures

insulin sensitivity
insulin sensitivity measured by oral glucose tolerance test at the beginning of the first, randomised diet
insulin sensitivity
insulin sensitivty measured by oral glucose tolerance test after the first diet
insulin sensitivity
Insulin sensitivity measured by oral glucose tolerance test in the beginning of the second, randomised diet
insulin sensitivity
insulin sensitivity measured by oral glucose tolerance test after the second diet

Secondary Outcome Measures

peripheral blood mononuclear cell gene expression
peripheral blood mononuclear cell gene expression
serum lipids
serum lipids, including serum lipidomics and fatty acid composition
serum lipids
serum lipids, including serum lipidomics and fatty acid composition
inflammation
inflammation measured as serum cytokines and adipose tissue inflammation
inflammation
inflammation measured as serum cytokines and adipose tissue inflammation
energy expenditure
energy expenditure and the rates of substrate oxidation
energy expenditure
energy expenditure and the rates of substrate oxidation
insulin secretion
insulin secretion
adipose tissue gene expression
adipose tissue gene expression

Full Information

First Posted
January 10, 2011
Last Updated
April 16, 2012
Sponsor
Marjukka Kolehmainen
Collaborators
Kuopio University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01274091
Brief Title
Gene - Diet Interactions
Acronym
Genediet
Official Title
Gene-diet Interactions
Study Type
Interventional

2. Study Status

Record Verification Date
April 2012
Overall Recruitment Status
Completed
Study Start Date
August 2010 (undefined)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
December 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Marjukka Kolehmainen
Collaborators
Kuopio University Hospital

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Interactions between genes and environment, i.e. our inherited responses to environmental changes, may be crucial in the development of the common diseases. The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect on seems to depend on intervention and age. In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene. Aim of the study: To test if subjects with Pro12Pro and Ala12Ala genotypes respond differentially to a diet supplemented with high saturated (SAFA) or polyunsaturated fat (PUFA). Hypotheses: Specific: Subjects with the Ala12Ala genotype will be more sensitive to dietary modification, and therefore respond more favorably to PUFA diet More general: Dietary instructions individually tailored according to the genotype would allow better treatment of obesity and diabetes
Detailed Description
Obesity and type 2 diabetes are increasing in all western countries, including Finland. Recent genome wide analyses have found > 30 genes that contribute to either condition.. However, none of these genes explain >5% of the disease risk and altogether they explain < 10% of the total disease risk in cross-sectional studies. Therefore, diet and physical activity are still the major determinants of the risk, as demonstrated by our earlier intervention studies in order to find out the effect of different dietary modifications on glucose and lipid metabolism. More importantly, interactions between genes and environment, i.e. our inherited responses to environmental changes, may be crucial in the development of the common diseases. Unfortunately, gene-environment interaction can only be effectively investigated in intervention studies that are more expensive than cross-sectional population screenings. This leads to a lower sample size and reduced power to detect effects of minor alleles. Despite these limitations the investigators have been able to demonstrate gene-intervention interactions for several genes, including PPARG, in the Finnish Diabetes Prevention study. There is an urgent need for studies investigating effects of tailored diets in individuals selected based on their genotype. This will be the next essential step leading to improved dietary treatments guided by genetic information. The investigators were the first to identify PPARG gene as risk gene for type 2 diabetes. The role of the Pro12Ala polymorphism in diabetes risk has also been verified in meta-analysis. However, this effect on seems to depend on intervention and age. Based on these findings the investigators created in collaboration with Johan Auwerx an Pro12Ala animal model that demonstrated a differential effect of dietary fat composition depending on the genotype. However, an important conclusive proof that subjects selected based on their Pro12Ala genotype would respond differently to specifically tailored diet modification is still needed. In this study the effects of diets high with saturated fatty acids (SAFA) and polyunsaturated fatty acids (PUFA) are compared in subjects carrying either Pro12Pro or Ala12Ala genotype of the PPARG gene. As a primary endpoint the investigators expect insulin sensitivity to alter differently depending on the genotype. Additionally, a detailed characterization of energy, glucose and lipid metabolism will be performed. Because PPARG gene plays a central role in adipogenesis one of the aims of this study is to find new pathways, genes and gene clusters that are regulated by PPARG in humans.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Insulin Sensitivity
Keywords
Gene-diet interaction, PPARgamma gene, Pro12Ala, Fatty acids, Dietary modification, Insulin sensitivity, Glucose metabolism

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
P/S-ratio 1.0
Arm Type
Experimental
Arm Description
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
Arm Title
P/S-ration 0.3
Arm Type
Experimental
Arm Description
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates:. Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
Intervention Type
Other
Intervention Name(s)
PUFA-diet
Intervention Description
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
Intervention Type
Other
Intervention Name(s)
SAFA-diet
Intervention Description
Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
Primary Outcome Measure Information:
Title
insulin sensitivity
Description
insulin sensitivity measured by oral glucose tolerance test at the beginning of the first, randomised diet
Time Frame
week 0
Title
insulin sensitivity
Description
insulin sensitivty measured by oral glucose tolerance test after the first diet
Time Frame
week 8
Title
insulin sensitivity
Description
Insulin sensitivity measured by oral glucose tolerance test in the beginning of the second, randomised diet
Time Frame
week 10
Title
insulin sensitivity
Description
insulin sensitivity measured by oral glucose tolerance test after the second diet
Time Frame
week 18
Secondary Outcome Measure Information:
Title
peripheral blood mononuclear cell gene expression
Time Frame
week 8
Title
peripheral blood mononuclear cell gene expression
Time Frame
week 18
Title
serum lipids
Description
serum lipids, including serum lipidomics and fatty acid composition
Time Frame
week 8
Title
serum lipids
Description
serum lipids, including serum lipidomics and fatty acid composition
Time Frame
week 18
Title
inflammation
Description
inflammation measured as serum cytokines and adipose tissue inflammation
Time Frame
week 8
Title
inflammation
Description
inflammation measured as serum cytokines and adipose tissue inflammation
Time Frame
week 18
Title
energy expenditure
Description
energy expenditure and the rates of substrate oxidation
Time Frame
week 8
Title
energy expenditure
Description
energy expenditure and the rates of substrate oxidation
Time Frame
week 18
Title
insulin secretion
Time Frame
week 8
Title
insulin secretion
Time Frame
week 18
Title
adipose tissue gene expression
Time Frame
week 8
Title
adipose tissue gene expression
Time Frame
week 18

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI >20kg/m2 <29kg/m2 Pro12Pro and Ala12Ala genotypes of PPARG Pro12Ala polymorphism participation to METSIM-study (METabolic Syndrome in Men, currently >10000 men included from the population living in Kuopio, principal investigator Markku Laakso) normoglycemia Exclusion Criteria: type 2 diabetes other chronic diseases
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jussi Pihlajamäki, Professor
Organizational Affiliation
University of Eastern Finland, Kuopio University Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ursula S Schwab, Clinical Lect, adjunct prof
Organizational Affiliation
University of Eastern Finland
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Matti Uusitupa, Professor
Organizational Affiliation
Professor
Official's Role
Study Chair
Facility Information:
Facility Name
University of Eastern Finland
City
Kuopio
ZIP/Postal Code
FIN-70211
Country
Finland

12. IPD Sharing Statement

Learn more about this trial

Gene - Diet Interactions

We'll reach out to this number within 24 hrs